Table 4 Patient characteristics
Overall | nmCRPC | mCRPC | mCNPC | |
|---|---|---|---|---|
N = 2667 | N = 1783 | N = 630 | N = 454 | |
Age on the index date (years) | ||||
Mean (SD) | 77.5 (8.08) | 78.3 (7.99) | 76.3 (7.92) | 76.2 (8.40) |
Median | 78 | 79 | 76 | 76 |
IQR (Q1:Q3) | 11 (72–83) | 11 (73–84) | 11 (71–82) | 12 (70–82) |
Age group at the index date, n (%) | ||||
18–49 | 1 (0.04%) | 0 (0.00%) | 1(0.16%) | 0 (0.00%) |
50–59 | 39 (1.46%) | 23 (1.29%) | 11 (1.75%) | 10 (2.20%) |
60–69 | 410 (15.37%) | 238 (13.35%) | 112 (17.78%) | 87 (19.16%) |
70–79 | 1075 (40.31%) | 683 (38.31%) | 283 (44.92%) | 189 (41.63%) |
80–89 | 994 (37.27%) | 724 (40.61%) | 200 (31.75%) | 145 (31.94%) |
90+ | 148 (5.55%) | 115 (6.45%) | 23 (3.65%) | 23 (5.07%) |
Height (centimeter) | ||||
Mean (SD) | 162.3 (7) | 162.3 (6.72) | 162.2 (8.01) | 162.1 (7.85) |
Median | 162 | 161 | 161 | 162 |
IQR (Q1:Q3) | 10 (156–166) | 10 (156–166) | 11 (155–166) | 9 (157–166) |
Missing | 710 | 548 | 129 | 63 |
Weight (kilogram) | ||||
Mean (SD) | 61.3 (11.00) | 61.7 (10.98) | 60.3 (11.60) | 60.5 (11.47) |
Median | 59.80 | 60.00 | 59.05 | 59.20 |
IQR (Q1:Q3) | 15.42 (51.58–67.00) | 15.37 (51.90–67.27) | 15.75 (50.00–65.75) | 15.02 (51.98–67.00) |
Missing | 696 | 539 | 124 | 62 |
eGFR (mL/min/1.73 m2) | ||||
Mean (SD) | 64.0 (21.53) | 63.1 (20.19) | 67.2 (25.27) | 63.7 (23.98) |
Median | 64.38 | 63.52 | 67.61 | 64.70 |
IQR (Q1:Q3) | 25.29 (50.88–76.17) | 24.79 (50.42–75.21) | 27.91 (54.00–81.91) | 25.29 (50.64–75.93) |
Missing | 18 | 17 | 0 | 1 |
ALT (U/L) | ||||
Mean (SD) | 22.2 (22.97) | 22.8 (24.26) | 21.1 (22.22) | 20.1 (14.41) |
Median | 17.0 | 18.0 | 16.0 | 16.5 |
IQR (Q1:Q3) | 12 (13.00–25.00) | 13 (13.00–26.00) | 10.25 (12.00–12.25) | 10 (13.00–23.00) |
Missing | 77 | 60 | 12 | 7 |
AST (U/L) | ||||
Mean (SD) | 27.4 (24.07) | 27.0 (21.88) | 28.8 (34.16) | 27.5 (16.72) |
Median | 23.0 | 23.0 | 23.0 | 23.5 |
IQR (Q1:Q3) | (19–29) | (19–29) | (18–29) | (19–30) |
Missing | 29 | 15 | 8 | 6 |
ALP (U/L) | ||||
Mean (SD) | 285.7 (596.58) | 201.5 (201.33) | 405.9 (660.83) | 557.5 (1236.11) |
Median | 175.0 | 169.0 | 188.0 | 231.8 |
IQR (Q1:Q3) | 96.5 (138.5–235.0) | 76.0 (134.5–210.5) | 153.5 (142.0–295.5) | 332.76 (154.12–486.88) |
Missing | 150 | 97 | 23 | 40 |
GGT(U/L) | ||||
Mean (SD) | 40.0 (59.11) | 37.9 (52.22) | 43.5 (77.55) | 48.3 (79.64) |
Median | 26 | 26 | 25 | 30 |
IQR (Q1:Q3) | 24 (17.0–41.0) | 23 (17.0–40.0) | 11 (18.0–29.0) | 24.75 (20.0–44.8) |
Missing | 881 | 620 | 208 | 120 |
Previous treatment for prostate cancer, n (%) | ||||
Any RP | 64 (2.40%) | 45 (2.52%) | 13 (2.06%) | 8 (1.76%) |
Any RT | 201 (7.54%) | 111 (6.23%) | 80 (12.70%) | 27 (5.95%) |
Any hormonal therapy | 1979 (74.20%) | 1419 (79.58%) | 550 (87.30%) | 157 (34.58%) |
Baseline PSA at the index date (ng/mL) | ||||
N | 2501 | 1783 | 630 | 288 |
Mean (SD) | 111.50 (606.15) | 29.52 (272.21) | 144.95 (545.85) | 629.28 (1429.08) |
Median (Min–Max) | 5.55 (0–12, 676.31) | 4.52 (2.01, 8519.69) | 12.15 (2.01, 9,070.83) | 100.2 (0, 12, 676.31) |
IQR(Q1-Q3) | 15.64 (2.99, 18.63) | 7.16 (2.82, 9.98) | 55.31 (4.40, 59.71) | 552.44 (14.66, 567.10) |
Missing | 166 | 0 | 0 | 166 |